Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An announcement from Illumina ( (ILMN) ) is now available.
On January 8, 2026, Illumina announced that veteran genomics leader Eric D. Green, M.D., Ph.D., former director of the U.S. National Human Genome Research Institute, will join the company as Chief Medical Officer effective February 2, 2026, reporting to the CEO and serving on the executive leadership team to help advance the clinical use of genomics, expand access to precision medicine, and increase diversity in genomic data. The company also disclosed that Chief Commercial Officer Everett Cunningham notified Illumina on January 4, 2026, that he will resign effective January 16, 2026, to become CEO of a life science tools company, with CEO Jacob Thaysen assuming the CCO responsibilities on an interim basis, signaling a significant reshaping of Illumina’s top leadership at a pivotal time for its medical and commercial strategy.
The most recent analyst rating on (ILMN) stock is a Hold with a $140.00 price target. To see the full list of analyst forecasts on Illumina stock, see the ILMN Stock Forecast page.
Spark’s Take on ILMN Stock
According to Spark, TipRanks’ AI Analyst, ILMN is a Outperform.
Illumina’s overall stock score is driven by strong earnings performance and positive technical indicators. The strategic financial move with the notes issuance supports future growth. However, valuation concerns and cash flow challenges slightly temper the score.
To see Spark’s full report on ILMN stock, click here.
More about Illumina
Illumina is a global leader in DNA sequencing and array-based technologies, focused on innovating genomic tools and solutions for customers across research, clinical, and applied markets. Its products support applications in life sciences, oncology, reproductive health, agriculture, and other emerging segments, positioning the company at the center of the rapidly expanding omics and precision medicine ecosystem.
Average Trading Volume: 1,762,273
Technical Sentiment Signal: Hold
Current Market Cap: $22.48B
Learn more about ILMN stock on TipRanks’ Stock Analysis page.